On November 22, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that Adelene Perkins, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference (Press release, Infinity Pharmaceuticals, NOV 22, 2021, View Source [SID1234595891]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be a fireside chat with Ted Tenthoff, Piper’s Senior Biotech Analyst, which will be available on the Company’s website beginning November 22nd. Management will also be available for 1-on-1 meetings with investors during the conference which will take place November 29th through December 2nd.

Presentation details can be found below:

33rd Annual Virtual Healthcare Conference
Format: Presentation and 1-on-1 meetings
Date and Time: Presentation available starting Monday, November 22nd at 10:00am ET; 1-on-1 meetings November 29th – December 2nd
The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.